Abstract
AbstractProstaglandin analogues are the most commonly used treatment choice in various forms of glaucoma. They have gained their popularity mostly by their efficacy, once a day dosing and their high systemic tolerability. However, the topical tolerability of the glaucoma drugs are in general is an issue; not only on the basis of quality of life of the patients but also as a factor of adherence and overall success of the glaucoma therapy. Tafluprost is a novel prostaglandin analogue. It has a high affinity and potent agonistic activity for prostaglandin F receptor. In non‐clinical and clinical phase !/II/III studies, tafluprost has shown an excellent IOP‐lowering effect. As a difluorinated prostaglandin analogue Tafluprost has also unique stability which makes it suitable for preservative free formulation. In this formulation it is proven to be efficacious and safe. In patients having ocular surface problems with a preserved prostaglandin analogue, a switch to preservative free tafluprost has shown to significantly reduce both symptoms and signs of ocular surface disease. Preservative‐free formulations of glaucoma drugs, now available also as a prostaglandin analogue, are tools in our armamentarium to target our medical management of glaucoma to balanced long term efficacy and safety.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
